This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010
Timeframe: 18 months
Dose-Escalation Stage: Safety of XB010
Timeframe: 18 months
Dose-Escalation Stage: Duration of exposure of XB010 [Tolerability]
Timeframe: 18 months
Dose-Escalation Stage: Dose intensity of XB010 [Tolerability]
Timeframe: 18 months
Cohort-Expansion Stage: Preliminary antitumor activity of XB010
Timeframe: 24 months